Table of Content

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Viral Vector Production Market

4. Market Overview
    4.1. Introduction
        4.1.1. Vector Type Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Viral Vector Production Market Analysis and Forecast, 2017-2031

5. Key Insights
    5.1. Evolution of Gene Therapy
    5.2. Pipeline Analysis
    5.3. Regulatory Scenario, by Region/Globally
    5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Viral Vector Production Market Analysis and Forecast, by Vector Type
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Vector Type, 2017-2031
        6.3.1. Adenovirus
        6.3.2. Adeno-associated virus
        6.3.3. Retroviruses
        6.3.4. Others (baculoviruses, lentivirus, etc.)
    6.4. Market Attractiveness Analysis, by Vector Type

7. Global Viral Vector Production Market Analysis and Forecast, by Disease
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Disease, 2017-2031
        7.3.1. Genetic Diseases
        7.3.2. Infectious Diseases
        7.3.3. Cancer
        7.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
    7.4. Market Attractiveness Analysis, by Disease

8. Global Viral Vector Production Market Analysis and Forecast, by Application
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Application, 2017-2031
        8.3.1. Gene Therapy
        8.3.2. Vaccinology
    8.4. Market Attractiveness Analysis, by Application

9. Global Viral Vector Production Market Analysis and Forecast, by Mode
    9.1. Introduction & Definition
    9.2. Key Findings / Developments
    9.3. Market Value Forecast, by Mode, 2017-2031
        9.3.1. Transient Transfection
        9.3.2. Stable Producer Cell Lines
    9.4. Market Attractiveness Analysis, by Mode

10. Global Viral Vector Production Market Analysis and Forecast, by End-user
    10.1. Introduction & Definition
    10.2. Key Findings / Developments
    10.3. Market Value Forecast, by End-user, 2017-2031
        10.3.1. Pharmaceutical & Biotechnology Companies
        10.3.2. Academic & Research Institutes
        10.3.3. CROs & CDMOs
    10.4. Market Attractiveness Analysis, by End-user

11. Global Viral Vector Production Market Analysis and Forecast, by Region
    11.1. Key Findings
    11.2. Market Value Forecast, by Region
        11.2.1. North America
        11.2.2. Europe
        11.2.3. Asia Pacific
        11.2.4. Latin America
        11.2.5. Middle East & Africa
    11.3. Market Attractiveness Analysis, by Region

12. North America Viral Vector Production Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Vector Type, 2017-2031
        12.2.1. Adenovirus
        12.2.2. Adeno-associated virus
        12.2.3. Retroviruses
        12.2.4. Others (baculoviruses, lentivirus, etc.)
    12.3. Market Value Forecast, by Disease, 2017-2031
        12.3.1. Genetic Diseases
        12.3.2. Infectious Diseases
        12.3.3. Cancer
        12.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
    12.4. Market Value Forecast, by Application, 2017-2031
        12.4.1. Gene Therapy
        12.4.2. Vaccinology
    12.5. Market Value Forecast, by Mode, 2017-2031
        12.5.1. Transient Transfection
        12.5.2. Stable Producer Cell Lines
    12.6. Market Value Forecast, by End-user, 2017-2031
        12.6.1. Pharmaceutical & Biotechnology Companies
        12.6.2. Academic & Research Institutes
        12.6.3. CROs & CDMOs
    12.7. Market Value Forecast, by Country, 2017-2031
        12.7.1. U.S.
        12.7.2. Canada
    12.8. Market Attractiveness Analysis
        12.8.1. By Vector Type
        12.8.2. By Disease
        12.8.3. By Application
        12.8.4. By Mode
        12.8.5. By End-user
        12.8.6. By Country

13. Europe Viral Vector Production Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Vector Type, 2017-2031
        13.2.1. Adenovirus
        13.2.2. Adeno-associated virus
        13.2.3. Retroviruses
        13.2.4. Others (baculoviruses, lentivirus, etc.)
    13.3. Market Value Forecast, by Disease, 2017-2031
        13.3.1. Genetic Diseases
        13.3.2. Infectious Diseases
        13.3.3. Cancer
        13.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
    13.4. Market Value Forecast, by Application, 2017-2031
        13.4.1. Gene Therapy
        13.4.2. Vaccinology
    13.5. Market Value Forecast, by Mode, 2017-2031
        13.5.1. Transient Transfection
        13.5.2. Stable Producer Cell Lines
    13.6. Market Value Forecast, by End-user, 2017-2031
        13.6.1. Pharmaceutical & Biotechnology Companies
        13.6.2. Academic & Research Institutes
        13.6.3. CROs & CDMOs
    13.7. Market Value Forecast, by Country/Sub-region, 2017-2031
        13.7.1. Germany
        13.7.2. U.K.
        13.7.3. France
        13.7.4. Spain
        13.7.5. Italy
        13.7.6. Rest of Europe
    13.8. Market Attractiveness Analysis
        13.8.1. By Vector Type
        13.8.2. By Disease
        13.8.3. By Application
        13.8.4. By Mode
        13.8.5. By End-user
        13.8.6. By Country/Sub-region
14. Asia Pacific Viral Vector Production Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Vector Type, 2017-2031
        14.2.1. Adenovirus
        14.2.2. Adeno-associated virus
        14.2.3. Retroviruses
        14.2.4. Others (baculoviruses, lentivirus, etc.)
    14.3. Market Value Forecast, by Diseases, 2017-2031
        14.3.1. Genetic Diseases
        14.3.2. Infectious Diseases
        14.3.3. Cancer
        14.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
    14.4. Market Value Forecast, by Application, 2017-2031
        14.4.1. Gene Therapy
        14.4.2. Vaccinology
    14.5. Market Value Forecast, by Mode, 2017-2031
        14.5.1. Transient Transfection
        14.5.2. Stable Producer Cell Lines
    14.6. Market Value Forecast, by End-user, 2017-2031
        14.6.1. Pharmaceutical & Biotechnology Companies
        14.6.2. Academic & Research Institutes
        14.6.3. CROs & CDMOs
    14.7. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.7.1. China
        14.7.2. Japan
        14.7.3. India
        14.7.4. Australia & New Zealand
        14.7.5. Rest of Asia Pacific
    14.8. Market Attractiveness Analysis
        14.8.1. By Vector Type
        14.8.2. By Disease
        14.8.3. By Application
        14.8.4. By Mode
        14.8.5. By End-user
        14.8.6. By Country/Sub-region
15. Latin America Viral Vector Production Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Vector Type, 2017-2031
        15.2.1. Adenovirus
        15.2.2. Adeno-associated virus
        15.2.3. Retroviruses
        15.2.4. Others (baculoviruses, lentivirus, etc.)
    15.3. Market Value Forecast, by Disease, 2017-2031
        15.3.1. Genetic Diseases
        15.3.2. Infectious Diseases
        15.3.3. Cancer
        15.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
    15.4. Market Value Forecast, by Application, 2017-2031
        15.4.1. Gene Therapy
        15.4.2. Vaccinology
    15.5. Market Value Forecast, by Mode, 2017-2031
        15.5.1. Transient Transfection
        15.5.2. Stable Producer Cell Lines
    15.6. Market Value Forecast, by End-user, 2017-2031
        15.6.1. Pharmaceutical & Biotechnology Companies
        15.6.2. Academic & Research Institutes
        15.6.3. CROs & CDMOs
    15.7. Market Value Forecast, by Country/Sub-region, 2017-2031
        15.7.1. Brazil
        15.7.2. Mexico
        15.7.3. Rest of Latin America
    15.8. Market Attractiveness Analysis
        15.8.1. By Vector Type
        15.8.2. By Disease
        15.8.3. By Application
        15.8.4. By Mode
        15.8.5. By End-user
        15.8.6. By Country/Sub-region

16. Middle East & Africa Viral Vector Production Market Analysis and Forecast
    16.1. Introduction
        16.1.1. Key Findings
    16.2. Market Value Forecast, by Vector Type, 2017-2031
        16.2.1. Adenovirus
        16.2.2. Adeno-associated virus
        16.2.3. Retroviruses
        16.2.4. Others (baculoviruses, lentivirus, etc.)
    16.3. Market Value Forecast, by Disease, 2017-2031
        16.3.1. Genetic Diseases
        16.3.2. Infectious Diseases
        16.3.3. Cancer
        16.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
    16.4. Market Value Forecast, by Application, 2017-2031
        16.4.1. Gene Therapy
        16.4.2. Vaccinology
    16.5. Market Value Forecast, by Mode, 2017-2031
        16.5.1. Transient Transfection
        16.5.2. Stable Producer Cell Lines
    16.6. Market Value Forecast, by End-user, 2017-2031
        16.6.1. Pharmaceutical & Biotechnology Companies
        16.6.2. Academic & Research Institutes
        16.6.3. CROs & CDMOs
    16.7. Market Value Forecast, by Country/Sub-region, 2017-2031
        16.7.1. GCC Countries
        16.7.2. South Africa
        16.7.3. Rest of Middle East & Africa
    16.8. Market Attractiveness Analysis
        16.8.1. By Vector Type
        16.8.2. By Disease
        16.8.3. By Application
        16.8.4. By Mode
        16.8.5. By End-user
        16.8.6. By Country/Sub-region

17. Competition Landscape
    17.1. Market Player - Competition Matrix (By Tier and Size of companies)
    17.2. Market Share Analysis By Company (2021)
    17.3. Company Profiles
        17.3.1. Pfizer, Inc.
            17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.1.2. Test Type Portfolio
            17.3.1.3. Financial Overview
            17.3.1.4. SWOT Analysis
            17.3.1.5. Strategic Overview
        17.3.2. Johnson & Johnson
            17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.2.2. Test Type Portfolio
            17.3.2.3. Financial Overview
            17.3.2.4. SWOT Analysis
            17.3.2.5. Strategic Overview
        17.3.3. AstraZeneca
            17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.3.2. Test Type Portfolio
            17.3.3.3. Financial Overview
            17.3.3.4. SWOT Analysis
            17.3.3.5. Strategic Overview
        17.3.4. Sanofi
            17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.4.2. Test Type Portfolio
            17.3.4.3. Financial Overview
            17.3.4.4. SWOT Analysis
            17.3.4.5. Strategic Overview
        17.3.5. Novartis AG
            17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.5.2. Test Type Portfolio
            17.3.5.3. Financial Overview
            17.3.5.4. SWOT Analysis
            17.3.5.5. Strategic Overview
        17.3.6. Spark Therapeutics, Inc. (F. Hoffmann-La Roche Ltd.)
            17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.6.2. Test Type Portfolio
            17.3.6.3. Financial Overview
            17.3.6.4. SWOT Analysis
            17.3.6.5. Strategic Overview
        17.3.7. GlaxoSmithKline plc
            17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.7.2. Test Type Portfolio
            17.3.7.3. Financial Overview
            17.3.7.4. SWOT Analysis
            17.3.7.5. Strategic Overview
        17.3.8. Merck KGaA (Merck & Co., Inc.)
            17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.8.2. Test Type Portfolio
            17.3.8.3. Financial Overview
            17.3.8.4. SWOT Analysis
            17.3.8.5. Strategic Overview
        17.3.9. Lonza
            17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.9.2. Test Type Portfolio
            17.3.9.3. Financial Overview
            17.3.9.4. SWOT Analysis
            17.3.9.5. Strategic Overview
        17.3.10. FUJIFILM Diosynth Biotechnologies Inc.
            17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.10.2. Test Type Portfolio
            17.3.10.3. Financial Overview
            17.3.10.4. SWOT Analysis
            17.3.10.5. Strategic Overview
        17.3.11. Oxford Biomedica plc
            17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.11.2. Test Type Portfolio
            17.3.11.3. Financial Overview
            17.3.11.4. SWOT Analysis
            17.3.11.5. Strategic Overview
        17.3.12. Amgen Inc.
            17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.12.2. Test Type Portfolio
            17.3.12.3. Financial Overview
            17.3.12.4. SWOT Analysis
            17.3.12.5. Strategic Overview
        17.3.13. Ferring B.V.
            17.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.13.2. Test Type Portfolio
            17.3.13.3. Financial Overview
            17.3.13.4. SWOT Analysis
            17.3.13.5. Strategic Overview
        17.3.14. uniQure N.V.
            17.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.14.2. Test Type Portfolio
            17.3.14.3. Financial Overview
            17.3.14.4. SWOT Analysis
            17.3.14.5. Strategic Overview
        17.3.15. bluebird bio, Inc.
            17.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.15.2. Test Type Portfolio
            17.3.15.3. Financial Overview
            17.3.15.4. SWOT Analysis
            17.3.15.5. Strategic Overview
        17.3.16. GenScript ProBio
            17.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.16.2. Test Type Portfolio
            17.3.16.3. Financial Overview
            17.3.16.4. SWOT Analysis
            17.3.16.5. Strategic Overview
        17.3.17. Thermo Fisher Scientific, Inc.
            17.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.17.2. Test Type Portfolio
            17.3.17.3. Financial Overview
            17.3.17.4. SWOT Analysis
            17.3.17.5. Strategic Overview
        17.3.18. Gamaleya Research Institute
            17.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
            17.3.18.2. Test Type Portfolio
            17.3.18.3. Financial Overview
            17.3.18.4. SWOT Analysis
            17.3.18.5. Strategic Overview



List of Figures

List of Figures

Figure 01: Global Viral Vector Production Market Value (US$ Mn) Forecast, 2017-2032

Figure 02: Global Viral Vector Production Market Value Share, by Vector Type, 2022

Figure 03: Global Viral Vector Production Market Value Share, by Disease, 2022

Figure 04: Global Viral Vector Production Market Value Share, by Application, 2022

Figure 05: Global Viral Vector Production Market Value Share, by Mode, 2022

Figure 06: Global Viral Vector Production Market Value Share, by End-user, 2022

Figure 07: Global Viral Vector Production Market Value Share, by Region, 2022

Figure 08: Global Viral Vector Production Market Value Share Analysis, by Vector Type, 2022 and 2032

Figure 09: Global Viral Vector Production Market Attractiveness Analysis, by Vector Type, 2023-2031

Figure 10: Global Viral Vector Production Market (US$ Mn), by Adenovirus, 2017-2032

Figure 11 Global Viral Vector Production Market (US$ Mn), by Adeno-associated Virus, 2017-2031

Figure 12: Global Viral Vector Production Market (US$ Mn), by Retroviruses, 2017-2032

Figure 13: Global Viral Vector Production Market (US$ Mn), by Others, 2017-2032

Figure 14: Global Viral Vector Production Market Value Share Analysis, by Disease, 2022 and 2032

Figure 15: Global Viral Vector Production Market Attractiveness Analysis, by Disease, 2023-2031

Figure 16: Global Viral Vector Production Market (US$ Mn), by Genetic Diseases, 2017-2032

Figure 17: Global Viral Vector Production Market (US$ Mn), by Infectious Diseases, 2017-2032

Figure 18: Global Viral Vector Production Market (US$ Mn), by Cancer, 2017-2032

Figure 19: Global Viral Vector Production Market (US$ Mn), by Others, 2017-2032

Figure 20: Global Viral Vector Production Market Value Share Analysis, by Application, 2022 and 2032

Figure 21: Global Viral Vector Production Market Attractiveness Analysis, by Application, 2023-2032

Figure 22: Global Viral Vector Production Market (US$ Mn), by Gene therapy, 2017-2032

Figure 23: Global Viral Vector Production Market (US$ Mn), by Vaccinology, 2017-2032

Figure 24: Global Viral Vector Production Market Value Share Analysis, by Mode, 2022 and 2032

Figure 25: Global Viral Vector Production Market Attractiveness Analysis, by Mode, 2023-2032

Figure 26: Global Viral Vector Production Market (US$ Mn), by Transient Transfection, 2017-2032

Figure 27: Global Viral Vector Production Market (US$ Mn), by Stable Producer Cell Lines, 2017-2032

Figure 28: Global Viral Vector Production Market Value Share Analysis, by End-user, 2022 and 2032

Figure 29: Global Viral Vector Production Market Attractiveness Analysis, by End-user, 2023-2032

Figure 30: Global Viral Vector Production Market (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2017-2032

Figure 31: Global Viral Vector Production Market (US$ Mn), by Academic & Research Institutes, 2017-2032

Figure 32: Global Viral Vector Production Market Value Share Analysis, by Region, 2022 and 2032

Figure 33: Global Viral Vector Production Market Attractiveness Analysis, by Region, 2023-2032

Figure 34: North America Viral Vector Production Market Value (US$ Mn) Forecast, 2017-2032

Figure 35: North America Viral Vector Production Market Value Share Analysis, by Country, 2022 and 2032

Figure 36: North America Viral Vector Production Market Attractiveness Analysis, by Country, 2023-2032

Figure 37: North America Viral Vector Production Market Value Share Analysis, by Vector Type, 2022 and 2032

Figure 38: North America Viral Vector Production Market Attractiveness Analysis, by Vector Type, 2023-2032

Figure 39: North America Viral Vector Production Market Value Share Analysis, by Disease, 2022 and 2032

Figure 40: North America Viral Vector Production Market Attractiveness Analysis, by Disease, 2023-2032

Figure 41: North America Viral Vector Production Market Value Share Analysis, by Application, 2022 and 2032

Figure 42: North America Viral Vector Production Market Attractiveness Analysis, by Application, 2023-2032

Figure 43: North America Viral Vector Production Market Value Share Analysis, by Mode, 2022 and 2032

Figure 44: North America Viral Vector Production Market Attractiveness Analysis, by Mode, 2023-2032

Figure 45: North America Viral Vector Production Market Value Share Analysis, by End-user, 2022 and 2032

Figure 46: North America Viral Vector Production Market Attractiveness Analysis, by End-user, 2023-2032

Figure 47: Europe Viral Vector Production Market Value (US$ Mn) Forecast, 2017-2032

Figure 48: Europe Viral Vector Production Market Value Share Analysis, by Country/Sub-region, 2022 and 2032

Figure 49: Europe Viral Vector Production Market Attractiveness Analysis, by Country/Sub-region, 2023-2032

Figure 50: Europe Viral Vector Production Market Value Share Analysis, by Vector Type, 2022 and 2032

Figure 51: Europe Viral Vector Production Market Attractiveness Analysis, by Vector Type, 2023-2032

Figure 52: Europe Viral Vector Production Market Value Share Analysis, by Disease, 2022 and 2032

Figure 53: Europe Viral Vector Production Market Attractiveness Analysis, by Disease, 2023-2032

Figure 54: Europe Viral Vector Production Market Value Share Analysis, by Application, 2022 and 2032

Figure 55: Europe Viral Vector Production Market Attractiveness Analysis, by Application, 2023-2032

Figure 56: Europe Viral Vector Production Market Value Share Analysis, by Mode, 2022 and 2032

Figure 57: Europe Viral Vector Production Market Attractiveness Analysis, by Mode, 2023-2032

Figure 58: Europe Viral Vector Production Market Value Share Analysis, by End-user, 2022 and 2032

Figure 59: Europe Viral Vector Production Market Attractiveness Analysis, by End-user, 2023-2032

Figure 60: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, 2017-2032

Figure 61: Asia Pacific Viral Vector Production Market Value Share Analysis, by Country/Sub-region, 2022 and 2032

Figure 62: Asia Pacific Viral Vector Production Market Attractiveness Analysis, by Country/Sub-region, 2023-2032

Figure 63: Asia Pacific Viral Vector Production Market Value Share Analysis, by Vector Type, 2022 and 2032

Figure 64: Asia Pacific Viral Vector Production Market Attractiveness Analysis, by Vector Type, 2023-032

Figure 65: Asia Pacific Viral Vector Production Market Value Share Analysis, by Disease, 2022 and 2032

Figure 66: Asia Pacific Viral Vector Production Market Attractiveness Analysis, by Disease, 2023-2032

Figure 67: Asia Pacific Viral Vector Production Market Value Share Analysis, by Application, 2022 and 2032

Figure 68: Asia Pacific Viral Vector Production Market Attractiveness Analysis, by Application, 2023-2032

Figure 69: Asia Pacific Viral Vector Production Market Value Share Analysis, by Mode, 2022 and 2032

Figure 70: Asia Pacific Viral Vector Production Market Attractiveness Analysis, by Mode, 2023-2032

Figure 71: Asia Pacific Viral Vector Production Market Value Share Analysis, by End-user, 2022 and 2032

Figure 72: Asia Pacific Viral Vector Production Market Attractiveness Analysis, by End-user, 2023-2032

Figure 73: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, 2017-2032

Figure 74: Latin America Viral Vector Production Market Value Share Analysis, by Country/Sub-region, 2022 and 2032

Figure 75: Latin America Viral Vector Production Market Attractiveness Analysis, by Country/Sub-region, 2023-2032

Figure 76: Latin America Viral Vector Production Market Value Share Analysis, by Vector Type, 2022 and 2032

Figure 77: Latin America Viral Vector Production Market Attractiveness Analysis, by Vector Type, 2023-2032

Figure 78: Latin America Viral Vector Production Market Value Share Analysis, by Disease, 2022 and 2032

Figure 79: Latin America Viral Vector Production Market Attractiveness Analysis, by Disease, 2023-2032

Figure 80: Latin America Viral Vector Production Market Value Share Analysis, by Application, 2022 and 2032

Figure 81: Latin America Viral Vector Production Market Attractiveness Analysis, by Application, 2023-2032

Figure 82: Latin America Viral Vector Production Market Value Share Analysis, by Mode, 2022 and 2032

Figure 83: Latin America Viral Vector Production Market Attractiveness Analysis, by Mode, 2023-2032

Figure 84: Latin America Viral Vector Production Market Value Share Analysis, by End-user, 2022 and 2032

Figure 85: Latin America Viral Vector Production Market Attractiveness Analysis, by End-user, 2023-2032

Figure 86: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, 2017-2032

Figure 87: Middle East & Africa Viral Vector Production Market Value Share Analysis, by Country/Sub-region, 2022 and 2032

Figure 88: Middle East & Africa Viral Vector Production Market Attractiveness Analysis, by Country/Sub-region, 2023-2032

Figure 89: Middle East & Africa Viral Vector Production Market Value Share Analysis, by Vector Type, 2022 and 2032

Figure 90: Middle East & Africa Viral Vector Production Market Attractiveness Analysis, by Vector Type, 2023-2032

Figure 91: Middle East & Africa Viral Vector Production Market Value Share Analysis, by Disease, 2022 and 2032

Figure 92: Middle East & Africa Viral Vector Production Market Attractiveness Analysis, by Disease, 2023-2032

Figure 93: Middle East & Africa Viral Vector Production Market Value Share Analysis, by Application, 2022 and 2032

Figure 94: Middle East & Africa Viral Vector Production Market Attractiveness Analysis, by Application, 2023-2032

Figure 95: Middle East & Africa Viral Vector Production Market Value Share Analysis, by Mode, 2022 and 2032

Figure 96: Middle East & Africa Viral Vector Production Market Attractiveness Analysis, by Mode, 2023-2032

Figure 97: Middle East & Africa Viral Vector Production Market Value Share Analysis, by End-user, 2022 and 2032

Figure 98: Middle East & Africa Viral Vector Production Market Attractiveness Analysis, by End-user, 2023-2032

Figure 99: Global Viral Vector Production Market Share, by Company, 2022

List of Tables

List of Tables

Table 01: Global Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032

Table 02: Global Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032

Table 03: Global Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032

Table 04: Global Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032

Table 05: Global Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032

Table 06: Global Viral Vector Production Market Value (US$ Mn) Forecast, by Region, 2017-2032

Table 07: North America Viral Vector Production Market Value (US$ Mn) Forecast, by Country, 2017-2032

Table 08: North America Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032

Table 09: North America Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032

Table 10: North America Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032

Table 11: North America Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032

Table 12: North America Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032

Table 13: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2032

Table 14: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032

Table 15: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032

Table 16: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032

Table 17: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032

Table 18: Europe Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032

Table 19: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2032

Table 20: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032

Table 21: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032

Table 22: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032

Table 23: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032

Table 24: Asia Pacific Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032

Table 25: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2032

Table 26: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032

Table 27: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032

Table 28: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032

Table 29: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032

Table 30: Latin America Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032

Table 31: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2032

Table 32: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by Vector Type, 2017-2032

Table 33: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by Disease, 2017-2032

Table 34: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by Application, 2017-2032

Table 35: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by Mode, 2017-2032

Table 36: Middle East & Africa Viral Vector Production Market Value (US$ Mn) Forecast, by End-user, 2017-2032